Wire · opportunities
FDA advisory panel recommends peptide Semax be added to pharmacy compounding list
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 July 2026 · Fusion42 review
An FDA advisory panel has recommended that Semax, a synthetic peptide, be added to the US pharmacy compounding list, allowing licensed pharmacies to compound and dispense the drug. This regulatory shift expands access to a nootropic peptide previously unavailable through conventional pharmacy channels.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you're building a direct-to-consumer nootropics or peptide brand, you just lost your exclusive distribution moat. Compounding pharmacies can now legally fill Semax prescriptions, which means you're competing on brand and customer acquisition instead of regulatory arbitrage.
◆ Coverage
1 source · 25 Jul 2026
◆ Related on Wire
◆ Topics